GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Net Debt Paydown Yield %

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Net Debt Paydown Yield % : 0.02% (As of May. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Clinuvel Pharmaceuticals's Net Debt Paydown Yield % was 0.02%.


Clinuvel Pharmaceuticals Net Debt Paydown Yield % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Net Debt Paydown Yield % Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.03 -0.03 0.02 0.02

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 - 0.02 0.02

Competitive Comparison of Clinuvel Pharmaceuticals's Net Debt Paydown Yield %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinuvel Pharmaceuticals's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Net Debt Paydown Yield % falls into.



Clinuvel Pharmaceuticals Net Debt Paydown Yield % Calculation

Clinuvel Pharmaceuticals's Net Debt Paydown Yield % for the quarter that ended in Dec. 2023 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 0.82-0.69 )/527.339196
=0.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Clinuvel Pharmaceuticals  (OTCPK:CLVLF) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Clinuvel Pharmaceuticals Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

CLINUVEL delivers second positive financial result

By Marketwired Marketwired 08-29-2018

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 07-09-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 05-20-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-19-2022

CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals

By Stock market mentor Stock market mentor 02-02-2023

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL Expands Pharmaceutical Portfolio

By Don Li2 Don Li2 11-08-2021

SCENESSE® to be Prescribed in China

By Marketwired Marketwired 04-23-2020

3 High-Performing Stocks

By Alberto Abaterusso Alberto Abaterusso 07-12-2019